Powerlifting peptide stacks: what the science actually supports

What did @powerlifting_portagee actually say?

The short version: they injected GHK-Cu and then tesamorelin into the same gluteal site late at night, noticed unusual bleeding after pulling the needle, and within minutes experienced intense burning and itching in their hands and feet plus throat tightness. They took diphenhydramine (Benadryl) and symptoms resolved in five to ten minutes. Their two theories were a sudden-onset allergy or accidental intravenous injection. They ended with a recommendation to keep Benadryl on hand if you use peptides.

To their credit, they did not downplay what happened. The phrase "burns like the power of a thousand suns" is dramatic, but the symptom cluster they described, pruritis at extremities, throat tightness, rapid onset after injection, is clinically recognizable. They also acknowledged uncertainty about the cause rather than declaring a definitive explanation. That kind of epistemic honesty is rare in peptide content.

Does the science back this up?

Both of their proposed mechanisms are plausible, and the existing literature gives each of them real support, though neither is proven for this specific incident.

On the allergy angle: type I hypersensitivity reactions to injected peptides are documented. GHK-Cu (glycine-histidine-lysine copper complex) has a long cosmetic and research history, but subcutaneous injection data in humans is thin. Tesamorelin, sold under the brand name Egrifta for HIV-associated lipodystrophy, carries a labeled warning for hypersensitivity reactions including urticaria, pruritus, and in rare cases anaphylaxis (FDA label, 2010). A 2012 review by Falutz in Best Practice and Research Clinical Endocrinology and Metabolism noted injection-site reactions occurring in roughly 6 percent of tesamorelin users in controlled trials. Sensitization over repeated exposure is a well-understood immunological pathway, so developing a reaction after six or seven weeks is not implausible.

On the accidental IV injection angle: intragluteal injections can nick the superior gluteal artery branches. Rapid systemic delivery of a vasoactive or immunogenic peptide could plausibly accelerate a reaction that would otherwise be slower or subclinical. The stream of blood they noticed is consistent with venous or arterial nick. This mechanism is harder to prove retroactively but is not invented.

What did they get wrong (or right)?

They got the clinical read mostly right. Bilateral hand and foot pruritus plus throat tightness minutes after injection is a textbook early anaphylaxis presentation. Reaching for diphenhydramine was a reasonable first response, and it worked here, but it is worth being direct: diphenhydramine is not first-line treatment for anaphylaxis. Epinephrine is. The 2015 WAO anaphylaxis guidelines (Simons et al., World Allergy Organization Journal) are unambiguous on this. Benadryl can help with hives and itch but does not reverse bronchospasm or cardiovascular collapse. If their throat had continued closing, diphenhydramine alone would not have been adequate.

They also casually mention mixing two peptides in the same glute site without flagging that as a variable worth controlling. If you're troubleshooting an adverse reaction, injecting two compounds simultaneously makes it impossible to identify which one caused the problem. That is a methodological failure that anyone using these compounds should care about.

The framing that the compounded versions they are using are equivalent to pharmaceutical-grade tesamorelin is implied but not stated explicitly. It is worth noting: compounded peptides sourced outside of licensed pharmacy channels have variable purity and sterility. Contamination is a real confound for adverse reactions.

What should you actually know?

If you inject peptides and experience sudden-onset bilateral pruritus, urticaria, throat tightness, or any drop in blood pressure, that is a medical emergency. Call 911. Do not scroll TikTok for a home remedy first. Diphenhydramine will not reliably abort anaphylaxis. The standard of care is intramuscular epinephrine, which is why people with known severe allergies carry EpiPens.

Beyond the emergency angle, there are practical harm-reduction points worth taking seriously. Aspirating before injection to check for blood return is debated for subcutaneous technique but becomes relevant when injecting into larger muscle groups. Injecting one compound at a time, in separate sites, on separate occasions, is the only way to isolate which peptide is causing a reaction. Keeping a log of compounds, doses, lot numbers, and any symptoms is basic safety hygiene that most social media peptide users skip entirely.

Finally: GHK-Cu and tesamorelin are not the same category of compound. GHK-Cu has minimal human clinical trial data for subcutaneous injection. Tesamorelin has a regulated pharmaceutical history and documented adverse event data. Treating them interchangeably from a safety standpoint is not supported by evidence.